Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reenergizing R&D: Sanofi Stirs The Pot, But Does It Have The Recipe?

Executive Summary

Sanofi-Aventis SA spent the past year culling drug candidates and reorganizing its research group in an attempt to shape up a shoddy pipeline. Now, though the company is in the midst of a hostile bid to acquire the biotech Genzyme – an acquisition attempt spurred by the fact the French drug maker doesn't have enough new drugs to make up for the ones it is losing to generics – management maintains that the reorganized research group is on track to become one of the most productive in the industry.
Advertisement

Related Content

Sanofi Reworks R&D To Tackle Risk, Meet Unmet Need
Sanofi Holds Brainstorming Sessions To Fuel Its Therapeutic Strategy Units
Empire State Of Mind: Lilly Aims To Build Academic Ties With N.Y. Research Center
Putting The Pieces Together Again: GSK Creates End-To-End Business Units
Deals Of The Week: GSK/Fondazione, Genentech/Biogen, Pfizer/Biocon…
Sanofi Makes Good On Outsourcing Promise In Deal With Covance
Sanofi-Aventis, MIT To Collaborate On Research Projects
Regeneron Secures Sanofi-Aventis Antibody Funding Through 2017
Sanofi-Aventis' New R&D Model Aims To Build A Network For Innovation
Sanofi-Aventis Grabs Start-up BiPar, Reels In Promising PARP Inhibitor For Cancer

Topics

Advertisement
UsernamePublicRestriction

Register

PS052761

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel